Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations

Koichi Takahashi, MD, Elias Jabbour, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MBBS, Jorge E. Cortes, MD, Tapan Kadia, Susan O'Brien, MD, Deborah A. Thomas, MD, Stefan Faderl, MD, Joyce Bass, RN, William G. Wierda, MD, PhD, Naval Daver, MD, Courtney D. DiNardo, MD, Sherry Pierce, Mark Brandt, Hagop M Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2013) 122 (21): 2684.

https://doi.org/10.1182/blood.V122.21.2684.2684

Published: 2013

Journal Articles

Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia

Gautam Borthakur, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Graciela Nogueras Gonzalez, Rajyalakshmi Luthra, PhD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Joyce Bass, Mark Brandt, Hagop M. Kantarjian, MD

Blood (2013) 122 (21): 3971.

https://doi.org/10.1182/blood.V122.21.3971.3971

Published: 2013

Journal Articles

Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen

Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Yin Cameron, MD, PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Hady Ghanem, MD, Tapan M. Kadia, M.D., Stefan Faderl, MD, Susan O'Brien, M.D., Michael S Mathisen, PharmD, Mark Brandt, BS, Naveen Pemmaraju, M.D., Deborah A. Thomas, MD, Joyce Bass, RN, Gautam Borthakur

Blood (2012) 120 (21): 3609.

https://doi.org/10.1182/blood.V120.21.3609.3609

Published: 2012

Journal Articles

Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

Gautam Borthakur, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, PhD, Dan Jones, MD, PhD, Varsha Gandhi, PhD, Zeev Estrov, MD, Susan O'Brien, M.D., Farhad Ravandi, MD, Joyce Bass, RN, Mark Brandt, Hagop Kantarjian, MD

Blood (2009) 114 (22): 2056.

https://doi.org/10.1182/blood.V114.22.2056.2056

Published: 2009

Journal Articles

Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarbine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

Gautam Borthakur, MD, Stefan Faderl, Srdan Verstovsek, Dan Jones, MD, PhD, Zeev Estrov, Susan O’Brien, Joyce Bass, Hagop Kantarjian

Blood (2008) 112 (11): 1937.

https://doi.org/10.1182/blood.V112.11.1937.1937

Published: 2008

NARROW

A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations

Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia

Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen

Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarbine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

Email alerts

ASH Publications

American Society of Hematology

A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations

Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia

Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen

Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarbine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only